Octreotide vs MK-677 (Ibutamoren)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →MK-677 (Ibutamoren)
MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.
Full details →Side-by-Side Comparison
| Aspect | Octreotide | MK-677 (Ibutamoren) |
|---|---|---|
| Mechanism | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. | Acts as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects. |
| Typical Dosage | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. | Typical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase. |
| Administration | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. | Oral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing. |
| Side Effects | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. | Increased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity. |
| Best For |